Anitocabtagene Autoleucel in RRMM: Efficacy, Safety, and Improving Access With Krina Patel, MD, MSc

Watch the full interview on Oncology Data Advisor: https://oncdata.com/anitocabtagene-autoleucel-krina-patel-md-msc BCMA‑directed CAR T‑cell therapy continues to transform expectations for relapsed/refractory multiple myeloma (RRMM). In this conversation, Krina Patel, MD, MSc, Section Chief for Multiple Myeloma and Director of Myeloma Clinical Research at the University of Texas MD Anderson Cancer Center, discusses new data for anitocabtagene autoleucel (anito‑cel) from the phase 2 IMAGINE‑1 study presented at ASH—highlighting deep, durable responses, a favorable safety profile, and what these findings could mean for expanding access, including outpatient CAR T delivery. Dr. Patel explains how anito‑cel’s unique D‑domain binding design may improve CAR T transfection, reduce inflammation through a fast off‑rate, and support a lower administered dose enriched for CAR‑positive T cells. She reviews IMAGINE‑1 results demonstrating a 96% overall response rate, 74% CR/sCR, high levels of MRD negativity at 10⁻⁵, and sustained MRD in the majority of reassessed patients. Safety signals remain reassuring, with minimal CRS/ICANS and no delayed neurotoxicities such as Parkinsonianism, cranial nerve palsies, or Guillain‑Barré syndrome. The discussion also puts anito‑cel in context with other BCMA‑directed CAR Ts, underscoring why quality of life and freedom from continuous therapy remain major advantages for patients. Dr. Patel shares insights into outpatient feasibility—where 9% of patients in IMAGINE‑1 were infused safely outside the hospital—and how strategies such as prophylactic tocilizumab may further support wider, community‑based CAR T access.